Investigation Report on China's Levothyroxine Market, 2010-2019

Levothyroxine is used for the treatment of congenital hypothyroidism (cretinism) and the long-term replacement treatment of hypothyroidism caused by various reasons. It can also be used in the suppressive therapy for simple goiter, chronic lymphatic thyroiditis, the suppressive therapy after thyroid cancer and the hyperthyroidism inhibition test.

DUBLIN, 03/09/2015 (informazione.it - comunicati stampa - editoria e media)

Levothyroxine has become the best-selling drug after entering various countries. It develops fast after entering China with annual sales value rising from less than CNY 15 million in 2005 to CNY 63.51 million in 2014 and CAGR during this period reaching up to 17.5%. Levothyroxine enjoys a vast demand in China. Merck (Germany), Berlin-Chemie AG (Germany) and China Associated Pharmaceutical all take up certain market share, among which Merck has the largest share of about 95% for sales value in 2014.

Key Topics Covered:

1 Related Concepts of Levothyroxine

2 Market Profile of Levothyroxine in China

3 Survey on Sales Status of Levothyroxine in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Levothyroxine in China, 2010-2014

5 Survey on Dosage Forms of Levothyroxine in China, 2010-2014

6 Reference Price of Levothyroxine in China in 2014

7 Major Manufacturers of Levothyroxine in Chinese Market, 2010-2014

8 Market Outlook of Levothyroxine in China, 2015-2019

Companies Mentioned

- Merck (Germany)

- China Associated Pharmaceutical